الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh  - entrectinib - cancer; carcinoma, non-small-cell lung - antineoplastična sredstva - rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (ntrk) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior ntrk inhibitorwho have no satisfactory treatment options. rozlytrek as monotherapy is indicated for the treatment of adult patients with ros1 positive, advanced non small cell lung cancer (nsclc) not previously treated with ros1 inhibitors.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh - pertuzumab, trastuzumab - neoplazme dojke - antineoplastična sredstva - early breast cancer (ebc)phesgo is indicated for use in combination with chemotherapy in:the neoadjuvant treatment of adult patients with her2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrencethe adjuvant treatment of adult patients with her2-positive early breast cancer at high risk of recurrencemetastatic breast cancer (mbc)phesgo is indicated for use in combination with docetaxel in adult patients with her2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-her2 therapy or chemotherapy for their metastatic disease.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - imunski sera in imunoglobulini, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. glej poglavja 4. 4 in 5.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh - mosunetuzumab - limfom, folikularni - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologi - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh  - glofitamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh - obinutuzumab - levkemija, limfocitna, kronična, b-celica - antineoplastična sredstva - kronično limfocitno levkemijo (cll)gazyvaro v kombinaciji z chlorambucil je indiciran za zdravljenje odraslih bolnikov s predhodno nezdravljenih kronično limfocitno levkemijo (cll) in z comorbidities česar so neprimerni za celoten odmerek fludarabine temelji terapije (glejte poglavje 5. folikularni limfom (fl)gazyvaro v kombinaciji s kemoterapijo, sledi gazyvaro vzdrževanje terapije pri pacientih, ki so dosegli odziv, ki je primerna za zdravljenje bolnikov s predhodno nezdravljenih napredno folikularni limfom. gazyvaro v kombinaciji z bendamustine sledi gazyvaro vzdrževanje je indiciran za zdravljenje bolnikov z folikularni limfom (fl), ki niso odzvali ali kdo napredoval med ali do 6 mesecev po zdravljenju z rituksimabom ali rituksimabom, ki vsebujejo režim.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh - ocrelizumab - multiple skleroza - imunosupresivi - zdravljenje odraslih bolnikov s ponavljajočo oblike multiple skleroze (rms) z aktivno boleznijo določi kliničnih ali slikanje funkcije. zdravljenje odraslih bolnikov z zgodnjim primarno progresivno multiplo sklerozo (ppms), v smislu bolezni, trajanje in stopnjo invalidnosti, in z imaging značilnosti značilno vnetno aktivnost.

الاتحاد الأوروبي - السلوفانية - EMA (European Medicines Agency)

roche registration gmbh  - pralsetinib - karcinom, pljučni pljuč - antineoplastična sredstva - gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (ret) fusion-positive advanced non-small cell lung cancer (nsclc) not previously treated with a ret inhibitor.

سلوفينيا - السلوفانية - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

servier pharma d.o.o. - bisoprolol; perindopril - filmsko obložena tableta - bisoprolol 8,49 mg / 1 tableta  perindopril3,395 mg / 1 tableta; perindopril 3,395 mg / 1 tableta - bisoprolol in perindopril